Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
ONC
BeiGene, Ltd.
BeiGene, Ltd. (ONC) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.7
/ 5.0
C+
Value
C
Factor Score
2.2
/ 5.0
Growth
B
Factor Score
3.3
/ 5.0
Profitability
B+
Factor Score
3.6
/ 5.0
Momentum
C
Factor Score
2.4
/ 5.0
Revisions
C-
Factor Score
1.9
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
73.1
EV / EBITDA
35.1
Rev Growth YoY
35.5%
Gross Margin
88.3%
Price Return 3M
8.7%
Price Return 12M
8.0%
Catalyst Signal
0.00
Market Cap
N/A
TTM Revenue
N/A
Price / Sales
5.8
ROE
12.4%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C (2.2) | B (3.3) | B+ (3.6) | C (2.4) | C- (1.9) | C+ (2.7) |
| 2026-08-04 | C (2.2) | B (3.3) | B+ (3.6) | C (2.4) | C- (1.9) | C+ (2.7) |
| 2026-08-03 | C- (2.1) | B- (3.1) | B (3.4) | C (2.4) | C- (2.0) | C+ (2.6) |
| 2026-08-02 | C- (2.1) | B- (3.1) | B (3.3) | C (2.4) | C- (1.9) | C+ (2.6) |